Gene Solutions to Spotlight MRD and Multi-Omics at SSO ASM 2025 in Singapore

  • News

Singapore, September 2025 – Gene Solutions will host an exclusive symposium titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors” during the 10th Annual Scientific Meeting of the Singapore Society of Oncology (SSO ASM 2025). The session will take place on Saturday, October 4, 2025, from 09:15 to 10:00 AM (GMT+8) at Grand Ballroom 1, Level 4, Grand Copthorne Waterfront, Singapore. 

  

As oncology moves toward increasingly personalized care, Molecular Residual Disease (MRD) and multi-omics integration are emerging as critical tools for improving patient outcomes. This symposium will bring together leading experts to share evidence-based strategies and practical insights for clinical adoption and regional collaboration.   

Program Highlights: 

  • Molecular Residual Disease (MRD) in Solid Tumors: Global and Asian Insights
    Speaker: Dr Lee Chern Siang, Raffles Cancer Centre
    Dr Lee will explore the clinical utility of ctDNA-based MRD assays, including their role in recurrence monitoring, adjuvant therapy strategies, and immunotherapy management. Attendees will gain clarity on tumor-informed vs. tumor-agnostic strategies and the evolving guideline landscape. 
  • Multi-Omics and MRD Synergy to Empower Precision Oncology
    Speaker: Asst Prof Dr Tan Chia-Ken Aaron, National Cancer Centre Singapore
    Dr Tan will demonstrate how integrating DNA/RNA profiling with MRD enhances biomarker discovery, detects resistance early, and informs therapy selection. Real-world case studies will illustrate endtoend workflows—from tissue and liquid samples to results of longitudinal monitoring.  
  • Panel Discussion: Multi-Omics in APAC — Adoption, Evidence, and Next Steps
    Moderated by Ida D. Lindstroem, Global Medical Affairs Director, Gene Solutions, this dialogue will address practical considerations for implementing multi-omics workflows and opportunities for regional collaboration. 

Why this matters:
With cancer incidence rising across Asia, precision oncology is no longer optional—it is essential. This session offers oncology leaders actionable insights for MRD and multi-omics integration, supported by global evidence and APAC-specific data. 

Join us at SSO ASM 2025 to be part of the conversation shaping the future of cancer care.
For more information, visit SSO ASM 2025 website or contact Gene Solutions. 

Download Program Booklet here:  https://ssoasm.com/programme-overview/  

Molecular Residual Disease (MRD) in Solid Tumors: Global and Asian Insights Speaker: Dr Lee Chern Siang, Raffles Cancer Centre Dr Lee will explore the clinical utility of ctDNA-based MRD assays, including their role in recurrence monitoring, adjuvant therapy strategies, and immunotherapy management. Attendees will gain clarity on tumor-informed vs. tumor-agnostic strategies and the evolving guideline landscape. Multi-Omics and MRD Synergy to Empower Precision Oncology Speaker: Asst Prof Dr Tan Chia-Ken Aaron, National Cancer Centre Singapore Dr Tan will demonstrate how integrating DNA/RNA profiling with MRD enhances biomarker discovery, detects resistance early, and informs therapy selection. Real-world case studies will illustrate endtoend workflows—from tissue and liquid samples to results of longitudinal monitoring. Panel Discussion: Multi-Omics in APAC — Adoption, Evidence, and Next Steps Moderated by Ida D. Lindstroem, Global Medical Affairs Director, Gene Solutions, this dialogue will address practical considerations for implementing multi-omics workflows and opportunities for regional collaboration.

Facebook
Twitter
Pinterest

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More